How much does the Indian version of the targeted drug Venetoclax cost?

Venetoclax/Venetoclax (Venetoclax) is a targeted therapy drug mainly used to treat chronic lymphocytic leukemia (CLL) and related hematological malignancies. Its unique mechanism of action enables it to show significant clinical efficacy, especially for some refractory or relapsed cases.

At present, there are no Indian generic drugs officially marketed abroad, only the Laos and Bangladesh versions of Venetoclax/Venetoclax generic drugs. Venetoclax/Venetoclax has been launched in China and has been included in medical insurance, and patients can purchase it domestically. Specifications: 100mg*14tablets and the price is around 5,000yuan. Please consult the local hospital pharmacy for specific prices. There are original drugs and generic drugs abroad. The Turkish version of Venetoclax/Venetoclaxoriginal drug on the market overseas, specification: 100mg*112 tablets, costs about 10,000 per box.

Foreign generic drugs are relatively cheaper. For example, the generic drugs listed in Laos and Bangladesh, the price of 100mg*120 tablets is around more than 4,000 yuan. The ingredients of original drugs and generic drugs are basically the same.

The main effect of this drug is by inhibiting the BCL-2 (BCL-2) protein, which is overexpressed in some hematological malignancies. BCL-2The protein inhibits the cell's self-destruction mechanism, making cancer cells resistant to apoptosis (programmed cell death). Through the action of Venetoclax/Venetoclax, the anti-apoptotic mechanism of cancer cells is broken, causing the cancer cells to self-destruct, thereby inhibiting the progression of the disease.

Venekra/Venetoclax has achieved significant breakthroughs in the treatment of CLL and related hematological malignancies, especially in patients who have limited or failed to respond to other treatment options. Clinical trial results show that among patients using venetoclax/venetoclax, many show good responses to treatment, even complete pathological and clinical responses, bringing new treatment hope to patients.

xa0